




Claims:

1. A compound represented by Formula I-X:



or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein:

R^{16} is selected from R^1 , H , $(C_4-C_6)alkyl$, $-OR^3$, $-SR^3$, $=O$, $-NR^3C(O)OR^3$, $-NR^3C(O)N(R^3)_2$, $-NR^3S(O)_2OR^3$, $-NR^3S(O)_2N(R^3)_2$, $-NR^3S(O)_2R^3$, $(C_6-C_{10})aryl$, and 5-7 membered heteroaryl containing 1-2 heteroatoms independently selected from O, N, and S,





 and , wherein the aryl and heteroaryl is optionally substituted with one or more substituents each independently selected from alkyl, hydroxyalkyl, haloalkyl, $(C_1-C_{10})alkoxy$, halogen, and hydroxyl;

R^{26} is selected from $=N-R^1$, and $=O$, $-OR^3$, and $-N-OR^3$;

R^{28} is selected from R^1 , $-OR^3$, $-OC(O)O(C(R^3)_2)_n$, $-OC(O)N(R^3)_2$, $-OS(O)_2N(R^3)_2$, and $-N(R^3)S(O)_2OR^3$;

R^{32} is selected from $=N-R^1$, H , $=O$, $-OR^3$, and $=N-OR^3$, $=N-NHR^3$, and $N(R^3)_2$;

R^{40} is selected from R^1 , $-OR^3$, and $-SR^3$, $-N_3$, $-N(R^3)_2$, $-NR^3C(O)OR^3$, $-NR^3C(O)N(R^3)_2$, $-NR^3S(O)_2OR^3$, $-NR^3S(O)_2N(R^3)_2$, $-NR^3S(O)_2R^3$, $-OP(O)(OR^3)_2$,

$-OP(O)(R^3)_2$, $-NR^3C(O)R^3$, $-S(O)R^3$, $-S(O)_2R^3$, $-OS(O)_2NHC(O)R^3$, , , , and  R^3 ;

wherein the compound comprises one R^1 ;

R¹ is -A-L¹-B; and

wherein


A is absent or is selected from ~~-(C(R³)₂)_n-~~, -O(C(R³)₂)_n-, ~~NR³(C(R³)₂)_n-~~,
-O(C(R³)₂)_n-[O(C(R³)₂)_n]_o-O(C(R³)₂)_p-, ~~C(O)(C(R³)₂)_n-~~, ~~C(O)NR³-~~, ~~NR³C(O)(C(R³)₂)_n-~~,
~~NR³C(O)O(C(R³)₂)_n-~~, -OC(O)NR³(C(R³)₂)_n-, ~~NHSO₂NH(C(R³)₂)_n-~~,
~~-OC(O)NHSO₂NH(C(R³)₂)_n-~~,
~~-O(C(R³)₂)_n-(C₆-C₁₀)arylene-~~,
~~-O(C(R³)₂)_n-heteroarylene-~~,
~~-OC(O)NH(C(R³)₂)_n-(C₆-C₁₀)arylene-~~,
~~-O-(C₆-C₁₀)arylene-~~,
~~-O-heteroarylene-~~,
-heteroarylene-(C₆-C₁₀)arylene-,
~~-O(C(R³)₂)_n-(C₆-C₁₀)arylene-(C₆-C₁₀)arylene-~~,
~~-O(C(R³)₂)_n-heteroarylene-heteroarylene-~~,
~~-O(C(R³)₂)_n-(C₆-C₁₀)arylene-heteroarylene-(C(R³)₂)_n-~~,
~~-O(C(R³)₂)_n-(C₆-C₁₀)arylene-heteroarylene-O(C(R³)₂)_n-~~,
~~-O(C(R³)₂)_n-(C₆-C₁₀)arylene-heteroarylene-NR³(C(R³)₂)_n-~~,
~~-O(C(R³)₂)_n-heteroarylene-heterocyclylene-C(O)(C(R³)₂)_n-~~,
~~-heteroarylene-(C₆-C₁₀)arylene-(C₆-C₁₀)arylene-~~,
~~-heteroarylene-(C₆-C₁₀)arylene-heteroarylene-O(C(R³)₂)_n-~~,
~~-heteroarylene-(C₆-C₁₀)arylene-heteroarylene-(C(R³)₂)_{n2}-O(C(R³)₂)_n-~~,
~~-O(C(R³)₂)_n-heteroarylene-heteroarylene-NR³-(C₆-C₁₀)arylene-~~,
~~-O(C(R³)₂)_n-heteroarylene-heteroarylene-heterocyclylene-(C(R³)₂)_n-~~,
~~-O(C(R³)₂)_n-heteroarylene-heteroarylene-heterocyclylene-C(O)(C(R³)₂)_n-~~,
-O(C(R³)₂)_n-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-(C(R³)₂)_n-,
-O(C(R³)₂)_n-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-C(O)(C(R³)₂)_n-,
-O(C(R³)₂)_n-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-SO₂(C(R³)₂)_n-,
-heteroarylene-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-(C(R³)₂)_n-,
-heteroarylene-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-C(O)(C(R³)₂)_n-, and
-heteroarylene-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-SO₂(C(R³)₂)_n-, ~~and~~
~~-O(C(R³)₂)_n-heteroarylene-heteroarylene-heterocyclylene-S(O)₂NR³-(C₆-C₁₀)arylene-~~,


wherein heteroarylene is 5-12 membered and contains 1-4 heteroatoms selected from O, N, and S; heterocyclylene is 5-12 membered and contains 1-4 heteroatoms selected from O, N, and S;


wherein the arylene, heteroarylene, and heterocyclylene are optionally substituted with one or more substituents each independently selected from (C₁-C₁₀)alkyl, and hydroxy(C₁-C₁₀)alkyl, haloalkyl, alkoxy, halogen, hydroxyl, —C(O)OR³, —C(O)N(R³)₂,

N(R³)₂, and alkyl substituted with N(R³)₂;

L¹ is selected from










wherein the bond with variable position in the triazole is in the 4-position ~~or 5-position, and wherein the A ring is phenylene or 5-8 membered heteroarylene;~~

B is selected from



B¹ is selected from $\text{---NR}^3\text{---}(\text{C}(\text{R}^3)_2)_n\text{---}$, $\text{---NR}^3\text{---}(\text{C}(\text{R}^3)_2)_n\text{---}(\text{C}_6\text{---C}_{10})\text{arylene---}(\text{C}(\text{R}^3)_2)_n\text{---}$, ~~$\text{---NR}^3\text{---}(\text{C}(\text{R}^3)_2)_n\text{---heteroarylene---}$~~ , $\text{---}(\text{C}_6\text{---C}_{10})\text{arylene---}$, ~~$\text{---NR}^3\text{---}(\text{C}(\text{R}^3)_2)_n\text{---NR}^3\text{C(O)---}$~~ , $\text{---NR}^3\text{---}(\text{C}(\text{R}^3)_2)_n\text{---heteroarylene---heterocyclylene---}(\text{C}_6\text{---C}_{10})\text{arylene---}$, ~~$\text{---heteroarylene---heterocyclylene---}(\text{C}_6\text{---C}_{10})\text{arylene---}$~~ , ~~$\text{---}\overset{\text{O}}{\parallel}\text{C---}(\text{C}(\text{R}^3)_2)_p\text{---}$~~ , ~~$\text{---}\overset{\text{O}}{\parallel}\text{C---}(\text{C}(\text{R}^3)_2)_p\text{---heteroarylene---}$~~ ,





$\text{NR}^3\text{-(C(R}^3\text{)}_2\text{)}_n\text{-S(O)}_2\text{-(C}_6\text{-C}_{10}\text{)arylene-C(O)-}$, wherein the --- bond on the left side of B^1 , as drawn, is bound to L^1 , the heteroarylene refers to a divalent radical derived from a heteroaryl selected from pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidyl, thiadiazolyl, oxadiazolyl, diazolyl, triazolyl, or tetrazolyl, and the heterocyclylene refers to a divalent radical derived from a heterocyclyl selected from oxetanyl, azetadiny, tetrahydrofuranyl, pyrrolidinyl, oxazoliny, oxazolidinyl, thiazoliny, thiazolidinyl, pyranly, thiopyranly, tetrahydropyranly, dioxaliny, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepiny, oxepiny, and diazepiny; and wherein the heteroaryl, heterocyclyl, and arylene are optionally substituted with (C₁-C₁₀)alkyl, hydroxyalkyl, halo(C₁-C₁₀)alkyl, alkoxy, or halogen, or hydroxyl;

each R^3 is independently H, or (C₁-C₆)alkyl, ~~C(O)(C₁-C₆)alkyl, C(O)NH-aryl, or C(S)NH-aryl~~, wherein the alkyl is unsubstituted or substituted with ~~COOH, (C₆-C₁₀)aryl or OH~~;

each R^4 is independently H, ~~(C₁-C₆)alkyl~~, halogen, 5-12 membered heteroaryl, 5-12 membered heterocyclyl, (C₆-C₁₀)aryl, wherein the heteroaryl, heterocyclyl, and aryl are optionally substituted with $\text{-N(R}^3\text{)}_2$, -OR^3 , ~~halogen, (C₁-C₆)alkyl, (C₄-C₆)alkylene-heteroaryl, (C₄-C₆)alkylene-CN, or -C(O)NR³-heteroaryl, or -C(O)NR³-heterocyclyl, and~~ wherein the heteroaryl refers to pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidyl, thiadiazolyl, oxadiazolyl, diazolyl, triazolyl, or tetrazolyl, and the heterocyclyl refers to oxetanyl, azetadiny, tetrahydrofuranyl, pyrrolidinyl, oxazoliny, oxazolidinyl, thiazoliny, thiazolidinyl, pyranly, thiopyranly, tetrahydropyranly, dioxaliny, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepiny, oxepiny, and diazepiny;

each Q is independently C(R³)₂ or O;

each Y is independently C(R³)₂ or a bond;

each n is independently a number from one to 12;


each o is independently a number from zero to 12;

each p is independently a number from zero to 12;


each q is independently a number from zero to 30; and

each r is independently 1, 2, 3, or 4;

provided that when R^{40} is R^1 , wherein R^1 is $-A-L^1-B$; L^1 is




2. A compound represented by Formula I-Xa:



or a pharmaceutically acceptable salt or oxepane isomer thereof, wherein:

R^{16} is selected from R^1 , H, (C_1-C_6) alkyl, $-\text{OR}^3$, $-\text{SR}^3$, $-\text{O}$, $-\text{NR}^3\text{C}(\text{O})\text{OR}^3$, $-\text{NR}^3\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{S}(\text{O})_2\text{OR}^3$, $-\text{NR}^3\text{S}(\text{O})_2\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{S}(\text{O})_2\text{R}^3$, $(\text{C}_6-\text{C}_{10})$ aryl, and 5-7




membered heteroaryl, and $-\text{C}(\text{R}^3)_2-$, wherein the aryl and heteroaryl is optionally substituted with one or more substituents each independently selected from alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen, and hydroxyl;

R^{26} is selected from $-\text{N}-\text{R}^1$, $-\text{O}$, $-\text{OR}^3$, and $-\text{N}-\text{OR}^3$;

R^{28} is selected from R^1 , $-\text{OR}^3$, $-\text{OC}(\text{O})\text{O}(\text{C}(\text{R}^3)_2)_n$, $-\text{OC}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{OS}(\text{O})_2\text{N}(\text{R}^3)_2$, and $-\text{N}(\text{R}^3)\text{S}(\text{O})_2\text{OR}^3$;

R^{32} is selected from $-\text{N}-\text{R}^1$, H, $-\text{O}$, $-\text{OR}^3$, $-\text{N}-\text{OR}^3$, $-\text{N}-\text{NHR}^3$, and $\text{N}(\text{R}^3)_2$;

R^{40} is selected from R^1 , $-\text{OR}^3$, $-\text{SR}^3$, $-\text{N}_3$, $-\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{C}(\text{O})\text{OR}^3$, $-\text{NR}^3\text{C}(\text{O})\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{S}(\text{O})_2\text{OR}^3$, $-\text{NR}^3\text{S}(\text{O})_2\text{N}(\text{R}^3)_2$, $-\text{NR}^3\text{S}(\text{O})_2\text{R}^3$, $-\text{OP}(\text{O})(\text{OR}^3)_2$,



wherein the compound comprises one R^1 ;

R^1 is $\text{--A--L}^1\text{--B--}$; and

wherein


A is absent or is selected from $\text{--(C(R}^3\text{)}_2\text{)}_n\text{--}$, $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--}$, $\text{--NR}^3\text{(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{[O(C(R}^3\text{)}_2\text{)}_n\text{]}_0\text{--O(C(R}^3\text{)}_2\text{)}_p\text{--}$, $\text{--C(O)(C(R}^3\text{)}_2\text{)}_n\text{--}$, $\text{--C(O)NR}^3\text{--}$, $\text{--NR}^3\text{C(O)(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--NR}^3\text{C(O)O(C(R}^3\text{)}_2\text{)}_n\text{--}$, $\text{--OC(O)NR}^3\text{(C(R}^3\text{)}_2\text{)}_n\text{--}$, $\text{--NHSO}_2\text{NH(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--OC(O)NHSO}_2\text{NH(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--heteroarylene--}$,
 $\text{--OC(O)NH(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--}$,
 $\text{--O--(C}_6\text{--C}_{10}\text{)arylene--}$,
 $\text{--O--heteroarylene--}$,
 $\text{--heteroarylene--(C}_6\text{--C}_{10}\text{)arylene--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--(C}_6\text{--C}_{10}\text{)arylene--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--heteroarylene--heteroarylene--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--O(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--NR}^3\text{(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--heteroarylene--heterocyclylene--C(O)(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--heteroarylene--(C}_6\text{--C}_{10}\text{)arylene--(C}_6\text{--C}_{10}\text{)arylene--}$,
 $\text{--heteroarylene--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--O(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--heteroarylene--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--(C(R}^3\text{)}_2\text{)}_{n2}\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--heteroarylene--heteroarylene--NR}^3\text{--(C}_6\text{--C}_{10}\text{)arylene--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--heteroarylene--heteroarylene--heterocyclylene--(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--heteroarylene--heteroarylene--heterocyclylene--C(O)(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--heterocyclylene--(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--heterocyclylene--C(O)(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--O(C(R}^3\text{)}_2\text{)}_n\text{--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--heterocyclylene--SO}_2\text{(C(R}^3\text{)}_2\text{)}_n\text{--}$,
 $\text{--heteroarylene--(C}_6\text{--C}_{10}\text{)arylene--heteroarylene--heterocyclylene--(C(R}^3\text{)}_2\text{)}_n\text{--}$


~~heteroarylene-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-C(O)(C(R³)₂)_n;~~
~~heteroarylene-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-SO₂(C(R³)₂)_n; and~~
~~O(C(R³)₂)_n-heteroarylene-heteroarylene-heterocyclylene-S(O)₂NR³-(C₆-C₁₀)arylene;~~



wherein heteroarylene is 5-12 membered and contains 1-4 heteroatoms selected from O, N, and S; heterocyclylene is 5-12 membered and contains 1-4 heteroatoms selected from O, N, and S;

wherein the arylene, heteroarylene, and heterocyclylene are optionally substituted with one or more substituents each independently selected from alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen, hydroxyl, C(O)OR³, C(O)N(R³)₂, N(R³)₂, and alkyl substituted with N(R³)₂;

L¹ is selected from










~~$\text{--NR}^3\text{--}(\text{C}(\text{R}^3)_2)_n\text{--heteroarylene heterocyclylene--}(\text{C}_6\text{--C}_{10})\text{arylene--}$~~ ~~$\text{--heteroarylene--}$~~

~~$\text{heterocyclylene--}(\text{C}_6\text{--C}_{10})\text{arylene--}$~~ ~~$\text{--}\overset{\text{O}}{\parallel}\text{C--}(\text{C}(\text{R}^3)_2)_p\text{--}$~~ ~~$\text{--}\overset{\text{O}}{\parallel}\text{C--}(\text{C}(\text{R}^3)_2)_p\text{--heteroarylene--}$~~ ,



~~$\text{--}\overset{\text{O}}{\parallel}\text{NR}^3\text{--}(\text{C}(\text{R}^3)_2)_n\text{--S(O)}_2\text{--arylene--C(O)--}$~~ , wherein the ~~$\text{--}\overset{\text{O}}{\parallel}\text{--}$~~ bond on the left side of B^1 , as drawn, is bound to L^1 ; and wherein the heteroaryl, heterocyclyl, and arylene are optionally substituted with alkyl, hydroxyalkyl, haloalkyl, alkoxy, halogen, or hydroxyl;

each R^3 is independently H, $(\text{C}_1\text{--C}_6)$ alkyl, $\text{C(O)}(\text{C}_1\text{--C}_6)$ alkyl, C(O)NH--aryl , or --C(S)NH--aryl , wherein the alkyl is unsubstituted or substituted with COOH , $(\text{C}_6\text{--C}_{10})\text{aryl}$ or OH ;

each R^4 is independently H, $(\text{C}_1\text{--C}_6)$ alkyl, halogen, 5-12 membered heteroaryl, 5-12 membered heterocyclyl, $(\text{C}_6\text{--C}_{10})\text{aryl}$, wherein the heteroaryl, heterocyclyl, and aryl are optionally substituted with $\text{N(R}^3)_2$, OR^3 , halogen, $(\text{C}_1\text{--C}_6)$ alkyl, $(\text{C}_1\text{--C}_6)$ alkylene-heteroaryl, $(\text{C}_1\text{--C}_6)$ alkylene-CN, $\text{C(O)NR}^3\text{--heteroaryl}$, or $\text{C(O)NR}^3\text{--heterocyclyl}$;

each Y is independently $\text{C(R}^3)_2$ or a bond;

each n is independently a number from one to 12;


each o is independently a number from zero to 12;

each p is independently a number from zero to 12;


each q is independently a number from zero to 30; and

each r is independently 1, 2, 3, or 4;

provided that when R^{40} is R^1 , wherein R^1 is $\text{A--L}^1\text{--B}$; L^1 is




23. A compound represented by Formula (I):



or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein:

R¹⁶ is selected from ~~R¹, H, (C₁-C₆)alkyl, -OR³, -SR³, =O, -NR³C(O)OR³, -NR³C(O)N(R³)₂, -NR³S(O)₂OR³, -NR³S(O)₂N(R³)₂, -NR³S(O)₂R³, (C₆-C₁₀)aryl, and 5-7~~ membered heteroaryl containing 1-2 heteroatoms independently selected from O, N, and S,





~~and~~ , wherein the aryl ~~and heteroaryl~~ is ~~optionally~~ substituted with one or more substituents each independently selected from alkyl, hydroxyalkyl, haloalkyl, (C₁-C₁₀)alkoxy, halogen, and hydroxyl;

R²⁶ is selected from =N-R¹, and =O, ~~OR³, and -N-OR³;~~

R²⁸ is selected from ~~R¹, -OR³, -OC(O)O(C(R³)₂)_n, -OC(O)N(R³)₂, -OS(O)₂N(R³)₂, and -N(R³)S(O)₂OR³;~~

R³² is selected from =N-R¹, ~~H, =O, -OR³, and =N-OR³;~~

R⁴⁰ is selected from R¹, -OR³, and -SR³; ~~N₃, -N(R³)₂, -NR³C(O)OR³, -NR³C(O)N(R³)₂, -NR³S(O)₂OR³, -NR³S(O)₂N(R³)₂, -NR³S(O)₂R³, -OP(O)(OR³)₂,~~

~~-OP(O)(R³)₂, -NR³C(O)R³, -S(O)R³, -S(O)₂R³, -OS(O)₂NHC(O)R³,~~ , ,
 , and  R³, and R³

wherein the compound comprises one R¹;

R¹ is -A-L¹-B; and

wherein


A is absent or selected from,


~~$-(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n-$~~ ,
 ~~$-NR^3(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n-[O(C(R^3)_2)_n]_o-O(C(R^3)_2)_p-$~~ ,
 ~~$-C(O)(C(R^3)_2)_n-$~~ ,
 ~~$-C(O)NR^3-$~~ ,
 ~~$-NR^3C(O)(C(R^3)_2)_n-$~~ ,
 ~~$-NR^3C(O)O(C(R^3)_2)_n-$~~ ,
 ~~$-OC(O)NR^3(C(R^3)_2)_n-$~~ ,
 ~~$-NHSO_2NH(C(R^3)_2)_n-$~~ ,
 ~~$-OC(O)NHSO_2NH(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n-(C_6-C_{10})\text{arylene}-$~~ ,
 ~~$-O(C(R^3)_2)_n\text{-heteroarylene}-$~~ ,
 ~~$-OC(O)NH(C(R^3)_2)_n-(C_6-C_{10})\text{arylene}-$~~ ,
 ~~$-O-(C_6-C_{10})\text{arylene}-$~~ ,
 ~~$-O\text{-heteroarylene}-$~~ ,
 ~~$\text{-heteroarylene-}(C_6-C_{10})\text{arylene-}$~~ ,
 ~~$-O(C(R^3)_2)_n-(C_6-C_{10})\text{arylene-}(C_6-C_{10})\text{arylene}-$~~ ,
 ~~$-O(C(R^3)_2)_n\text{-heteroarylene-heteroarylene}-$~~ ,
 ~~$-O(C(R^3)_2)_n-(C_6-C_{10})\text{arylene-heteroarylene-}(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n-(C_6-C_{10})\text{arylene-heteroarylene-O}(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n-(C_6-C_{10})\text{arylene-heteroarylene-NR}^3(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n\text{-heteroarylene-heterocyclylene-C}(O)(C(R^3)_2)_n-$~~ ,
 ~~$\text{-heteroarylene-}(C_6-C_{10})\text{arylene-}(C_6-C_{10})\text{arylene}-$~~ ,
 ~~$\text{-heteroarylene-}(C_6-C_{10})\text{arylene-heteroarylene-O}(C(R^3)_2)_n-$~~ ,
 ~~$\text{-heteroarylene-}(C_6-C_{10})\text{arylene-heteroarylene-}(C(R^3)_2)_{n2}\text{-O}(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n\text{-heteroarylene-heteroarylene-NR}^3-(C_6-C_{10})\text{arylene}-$~~ ,
 ~~$-O(C(R^3)_2)_n\text{-heteroarylene-heteroarylene-heterocyclylene-}(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n\text{-heteroarylene-heteroarylene-heterocyclylene-C}(O)(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n-(C_6-C_{10})\text{arylene-heteroarylene-heterocyclylene-}(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n-(C_6-C_{10})\text{arylene-heteroarylene-heterocyclylene-C}(O)(C(R^3)_2)_n-$~~ ,
 ~~$-O(C(R^3)_2)_n-(C_6-C_{10})\text{arylene-heteroarylene-heterocyclylene-SO}_2(C(R^3)_2)_n-$~~ ,

-heteroarylene-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-(C(R³)₂)_n-,
 -heteroarylene-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-C(O)(C(R³)₂)_n-, and
 -heteroarylene-(C₆-C₁₀)arylene-heteroarylene-heterocyclylene-SO₂(C(R³)₂)_n-, ~~and~~
~~-O(C(R³)₂)_n-heteroarylene-heteroarylene-heterocyclylene-S(O)₂NR³-(C₆-C₁₀)arylene-~~,

wherein heteroarylene is 5-12 membered and contains 1-4 heteroatoms selected from O, N, and S; heterocyclylene is 5-12 membered and contains 1-4 heteroatoms selected from O, N, and S;


wherein the arylene, heteroarylene, and heterocyclylene are optionally substituted with one or more substituents each independently selected from (C₁-C₁₀)alkyl, and hydroxy(C₁-C₁₀)alkyl, ~~haloalkyl, alkoxy, halogen, and hydroxyl~~;
 L¹ is selected from





wherein the bond with variable position in the triazole is in the 4-position ~~or 5-position~~, and wherein the A ring is phenylene or 5-8 membered heteroarylene;

B is selected from









B¹ is selected from $-\dot{\zeta}-\text{NR}^3-(\text{C}(\text{R}^3)_2)_n-$, $-\dot{\zeta}-\text{NR}^3-(\text{C}(\text{R}^3)_2)_n-(\text{C}_6-\text{C}_{10})\text{arylene}-$
 $(\text{C}(\text{R}^3)_2)_n-$, ~~$-\dot{\zeta}=\text{NR}^3-(\text{C}(\text{R}^3)_2)_n\text{-heteroarylene-}$~~ , $-\dot{\zeta}-(\text{C}_6-\text{C}_{10})\text{arylene-}$, ~~$-\dot{\zeta}=\text{NR}^3-(\text{C}(\text{R}^3)_2)_n\text{-}$~~
 ~~$\text{NR}^3\text{C}(\text{O})-$~~ ,

$-\dot{\zeta}-\text{NR}^3-(\text{C}(\text{R}^3)_2)_n\text{-heteroarylene-heterocyclylene-}(\text{C}_6-\text{C}_{10})\text{arylene-}$,

~~$-\dot{\zeta}=\text{heteroarylene-heterocyclylene-}(\text{C}_6-\text{C}_{10})\text{arylene-}$~~ , $-\dot{\zeta}-\overset{\text{O}}{\parallel}\text{C}-(\text{C}(\text{R}^3)_2)_p-$,

~~$\overset{\text{O}}{\parallel}\text{C}-(\text{C}(\text{R}^3)_2)_p\text{-heteroarylene-}$~~ ,



, wherein the $-\dot{\zeta}-$

bond on the left side of B¹, as drawn, is bound to L¹, the heteroarylene refers to a divalent radical derived from a heteroaryl selected from pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidyl, thiadiazolyl, oxadiazolyl, diazolyl, triazolyl, or tetrazolyl, and the heterocyclylene refers to a divalent radical derived from a heterocyclyl selected from oxetanyl, azetadiny, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranly, thiopyranly, tetrahydropyranly, dioxaliny, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepinyl, oxepinyl, and diazepinyl; and wherein the heteroaryl, heterocyclyl, and arylene are optionally substituted with (C₁-C₁₀)alkyl, hydroxyalkyl, halo(C₁-C₁₀)alkyl, alkoxy, or halogen, or hydroxyl;

each R³ is independently H or (C₁-C₆)alkyl;

each R⁴ is independently H, ~~(C₁-C₆)alkyl~~, halogen, 5-12 membered heteroaryl, 5-12 membered heterocyclyl, (C₆-C₁₀)aryl, wherein the heteroaryl, heterocyclyl, and aryl are optionally substituted with -N(R³)₂, -OR³, ~~halogen~~, (C₁-C₆)alkyl, ~~(C₁-C₆)alkylene-~~ heteroaryl, (C₁-C₆)alkylene-CN, or -C(O)NR³-heteroaryl, and wherein the heteroaryl refers to pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidyl, thiadiazolyl, oxadiazolyl, diazolyl, triazolyl, or tetrazolyl, and the heterocyclyl refers to oxetanyl, azetadiny, tetrahydrofuranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranly,

thiopyranyl, tetrahydropyranyl, dioxalanyl, piperidiny, morpholiny, thiomorpholiny, piperaziny, azepiny, oxepiny, and diazepiny;

each Q is independently C(R³)₂ or O;

each Y is independently C(R³)₂ or a bond;

each Z is independently H or absent;

each n is independently a number from one to 12;


each o is independently a number from zero to 12;

each p is independently a number from zero to 12;

each q is independently a number from zero to 10; and


each r is independently 1, 2, 3, or 4;

provided that when R⁴⁰ is R¹, wherein R¹ is -A-L¹-B; L¹ is




A is not -O(CH₂)₂-O(CH₂)₂-.

34. The compound of any one of claims 1-23, represented by Formula (Ia-X):




or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein R¹⁶ is -OR³R¹.

45. The compound of any one of claims 1-23, represented by Formula (Ib-X):




or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein R^{26} is $=N-R^1$.

[56.](#) The compound of any one of claims 1-[23](#), represented by Formula (Ic-X):




or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein R^{28} is R^1-OH .

[67.](#) The compound of any one of claims 1-[23](#), represented by Formula (Id-X):



or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein R^{32} is $=N-R^1$.

[78.](#) The compound of any one of claims 1-[23](#), represented by Formula (Ie-X):



or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein R^{40} is R^1 .

[89.](#) The compound of any one of claims 1-[23](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein A is $-O(C(R^3)_2)_n$.

[910.](#) The compound of any one of claims 1-[23](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein A is $-O(C(R^3)_2)_n-[O(C(R^3)_2)_n]_o-O(C(R^3)_2)_p$.

1011. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein A is $-\text{O}(\text{C}(\text{R}^3)_2)_n-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-(\text{C}(\text{R}^3)_2)_n-$.


1112. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein A is $-\text{heteroarylene}-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-(\text{C}(\text{R}^3)_2)_n-$, $-\text{heteroarylene}-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-\text{C}(\text{O})(\text{C}(\text{R}^3)_2)_n-$, $-\text{heteroarylene}-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-\text{SO}_2(\text{C}(\text{R}^3)_2)_n-$, or $-\text{O}(\text{C}(\text{R}^3)_2)_n-\text{heteroarylene-heteroarylene-heterocyclylene}-\text{S}(\text{O})_2\text{NR}^3-(\text{C}_6-\text{C}_{10})\text{arylene}-$.

1213. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein A is $-\text{O}(\text{C}(\text{R}^3)_2)_n-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-(\text{C}(\text{R}^3)_2)_n-$, $-\text{O}(\text{C}(\text{R}^3)_2)_n-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-\text{C}(\text{O})(\text{C}(\text{R}^3)_2)_n-$, or $-\text{O}(\text{C}(\text{R}^3)_2)_n-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-\text{SO}_2(\text{C}(\text{R}^3)_2)_n-$.


1314. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein A is ~~$-\text{heteroarylene}-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-(\text{C}(\text{R}^3)_2)_n-\text{O}(\text{C}(\text{R}^3)_2)_n-\text{heteroarylene-heteroarylene}-\text{NR}^3-(\text{C}_6-\text{C}_{10})\text{arylene}-, \text{O}(\text{C}(\text{R}^3)_2)_n-\text{heteroarylene-heteroarylene-heterocyclylene}-(\text{C}(\text{R}^3)_2)_n-$, or $-\text{O}(\text{C}(\text{R}^3)_2)_n-\text{heteroarylene-heteroarylene-heterocyclylene}-\text{C}(\text{O})(\text{C}(\text{R}^3)_2)_n-$~~ .

1415. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein A is ~~$-\text{heteroarylene}-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene-heterocyclylene}-\text{C}(\text{O})(\text{C}(\text{R}^3)_2)_n-$, $-\text{heteroarylene}-(\text{C}_6-\text{C}_{10})\text{arylene}-(\text{C}_6-\text{C}_{10})\text{arylene}-, \text{heteroarylene}-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene}-\text{O}(\text{C}(\text{R}^3)_2)_n-$, or $-\text{heteroarylene}-(\text{C}_6-\text{C}_{10})\text{arylene-heteroarylene}-(\text{C}(\text{R}^3)_2)_{n2}-\text{O}(\text{C}(\text{R}^3)_2)_n-$~~ .


1516. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt, **stereoisomer**, oxepane isomer, or tautomer thereof wherein L¹ is




1617. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt, **stereoisomer**, oxepane isomer, or tautomer thereof, wherein L¹ is




1718. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt, **stereoisomer**, oxepane isomer, or tautomer thereof, wherein L¹ is



1819. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt, **stereoisomer**, oxepane isomer, or tautomer thereof, wherein L¹ is




[1920](#). The compound of any one of claims 1-[32](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein L¹ is




[2021](#). The compound of claim [67](#), or a pharmaceutically acceptable salt, [stereoisomer](#),


oxepane isomer, or tautomer thereof, wherein L¹ is




[2122](#). The compound of claim [67](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein L¹ is




2223. The compound of claim 67, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein L^1 is




2324. The compound of claim 67, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein L^1 is



2425. The compound of claim 67, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein L^1 is




2526. The compound of claim 67, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein L^1 is




27. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or


oxepane isomer thereof, wherein L^1 is



2826. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein L¹ is




2927. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, wherein L¹ is




3028. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt,

[stereoisomer](#), oxepane isomer, or tautomer thereof, wherein B is



3129. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt,

[stereoisomer](#), oxepane isomer, or tautomer thereof, wherein B is




3230. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt,

[stereoisomer](#), oxepane isomer, or tautomer thereof, wherein B¹ is $^{-\zeta-} \text{NR}^3 \text{-(C(R}^3\text{))}_n \text{-}$.

3331. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt,

[stereoisomer](#), oxepane isomer, or tautomer thereof, wherein B¹ is







3432. The compound of any one of claims 1-**23**, or a pharmaceutically acceptable salt,


[stereoisomer](#), oxepane isomer, or tautomer thereof, wherein R⁴ is 5-12 membered heteroaryl,

wherein the heteroaryl is optionally substituted with $-N(R^3)_2$, $-OR^3$, halogen, $-(C_1-C_6)alkyl$, $-(C_4-C_6)alkylene\ heteroaryl$, $-(C_4-C_6)alkylene\ CN$, or $-C(O)NR^3$ -heteroaryl.


3533. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, stereoisomer, oxepane isomer, or tautomer thereof, wherein R^4 is 5-12 membered heteroaryl optionally substituted with $-NH_2$.

3634. A compound selected from the group consisting of:


Structure
 Example 1
 Example 2
 Example 3
 Example 4




Example 5




Example 6




Example 7




Example 8




Example 9




Example 10




Example 11




Example 12




Example 13




Example 14




Example 15




Example 16




Example 17




Example 18




Example 19




Example 20




Example 21




Example 22




Example 23




Example 24




Example 25




Example 26




Example 27




Example 28




Example 29




Example 30




Example 31




Example 32




Example 33




Example 34




Example 35




Example 36




Example 37




Example 38



Example 39




Example 40




Example 41







Example 46




Example 47




Example 48







Example 49




Example 50




Example 51







Example 56




Example 57




Example 58




Example 59




Example 60




Example 61




Example 62




Example 63




Example 64




Example 65




Example 66




Example 67




Example 68




Example 69




Example 70




Example 71




Example 72




Example 73




Example 74




Example 75




Example 76




Example 77




Example 78




Example 79




Example 80




Example 81




Example 82




Example 83




Example 84




Example 85




Example 86




Example 87




Example 88




Example 89




Example 90




Example 91




Example 92




Example 93




Example 94




Example 95




Example 96




Example 97




Example 98




Example 99




Example 100




Example 101




Example 102




Example 103




Example 104




Example 105




Example 106




Example 107




Example 108




Example 109




Example 110






Example 111




Example 112




Example 113







Example 121




Example 122




Example 123




Example 124




Example 125




Example 126




Example 127




Example 128




Example 129




Example 130







Example 136




Example 137







Example 138




Example 139




Example 140







Example 146




Example 147




Example 148




Example 149




Example 150




Example 151




Example 152




Example 153




Example 154




Example 155




Example 156




Example 157




Example 158




Example 159




Example 160




Example 161




Example 162




Example 163




Example 164




Example 165




Example 166




Example 167




Example 168




Example 169




Example 170




Example 171




Example 172




Example 173




Example 174




Example 175




Example 176




Example 177




Example 178




Example 179




Example 180




Example 181




Example 182




Example 183




Example 184




Example 185




Example 186




Example 187





Example 188




Example 189




Example 190







Example 195




Example 196




Example 197




Example 198




Example 199



Example 200



Example 201



Example 202

or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof.

[3537](#). A pharmaceutical composition comprising a compound of any one of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, and at least one of a pharmaceutically acceptable carrier, diluent, or excipient.

[3638](#). A compound of any one of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, for use in treating a disease or disorder mediated by mTOR selected from brain and neurovascular tumors, head and neck cancers, breast cancer, lung cancer, mesothelioma, lymphoid cancer, stomach cancer, kidney cancer, renal carcinoma, liver cancer, ovarian cancer, ovary endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neuro cancers, spleen cancers, pancreatic cancers, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulva cancer, prostate cancer, penile cancer, bone cancers, muscle cancers, soft tissue cancers, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, ocular cancer, gastrointestinal stromal tumors, neuro-endocrine tumors, resistance by transplantation of heart, kidney, liver, medulla ossium, skin, cornea, lung, pancreas, intestinum tenue, limb, muscle, nerves, duodenum, small-bowel, or pancreatic-islet-cell; graft-versus-host diseases brought about by medulla ossium transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, and glomerulonephritis.

[3739](#). A compound of any one of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, for use in preventing a disease or disorder mediated by mTOR selected from brain and neurovascular tumors, head and neck cancers, breast cancer, lung cancer, mesothelioma, lymphoid cancer, stomach cancer, kidney cancer, renal carcinoma, liver cancer, ovarian cancer, ovary endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neuro cancers, spleen cancers, pancreatic cancers, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulva cancer, prostate cancer, penile cancer, bone cancers, muscle cancers, soft tissue cancers, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, ocular cancer, gastrointestinal stromal tumors, neuro-endocrine tumors, resistance by transplantation of heart, kidney, liver, medulla ossium, skin, cornea, lung, pancreas, intestinum tenue, limb, muscle, nerves, duodenum, small-bowel, or pancreatic-islet-cell; graft-versus-host diseases brought about by medulla ossium transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, and glomerulonephritis.

[3840](#). A compound of any one of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, for use in reducing the risk of a disease or disorder mediated by mTOR selected from brain and neurovascular tumors, head and neck cancers, breast cancer, lung cancer, mesothelioma, lymphoid cancer, stomach cancer, kidney cancer, renal carcinoma, liver cancer, ovarian cancer, ovary endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neuro cancers, spleen cancers, pancreatic cancers, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulva cancer, prostate cancer, penile cancer, bone cancers, muscle cancers, soft tissue cancers, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, ocular cancer, gastrointestinal stromal tumors, neuro-endocrine tumors, resistance by transplantation of heart, kidney, liver, medulla ossium, skin, cornea, lung, pancreas, intestinum tenue, limb, muscle, nerves, duodenum, small-bowel, or pancreatic-islet-cell; graft-versus-host diseases brought about by medulla ossium transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, and glomerulonephritis.

[3941](#). A compound of any one of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, for use in treating cancer.

[4042](#). The compound for use of claim [3941](#), wherein the cancer is selected from brain and neurovascular tumors, head and neck cancers, breast cancer, lung cancer, mesothelioma, lymphoid cancer, stomach cancer, kidney cancer, renal carcinoma, liver cancer, ovarian cancer, ovary endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neuro cancers, spleen cancers, pancreatic cancers, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulva cancer, prostate cancer, penile cancer, bone cancers, muscle cancers, soft tissue cancers, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, ocular cancer, gastrointestinal stromal tumors, and neuro-endocrine tumors.

[4143](#). A compound of any one of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, for use in treating an immune-mediated disease selected from resistance by transplantation of heart, kidney, liver, medulla ossium,

skin, cornea, lung, pancreas, intestinum tenue, limb, muscle, nerves, duodenum, small-bowel, or pancreatic-islet-cell; graft-versus-host diseases brought about by medulla ossium transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, and glomerulonephritis.

[4244](#). A compound of any one of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, for use in treating [an age-related](#) condition selected from sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis, osteoarthritis, high blood pressure, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, diminished life expectancy, impaired kidney function, and age-related hearing loss, aging-related mobility disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, heart dysfunction such as cardiac hypertrophy and systolic and diastolic dysfunction, immunosenescence, cancer, obesity, and diabetes.

[4345](#). Use of a compound of any of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, or reducing the risk of a disease or disorder mediated by mTOR selected from brain and neurovascular tumors, head and neck cancers, breast cancer, lung cancer, mesothelioma, lymphoid cancer, stomach cancer, kidney cancer, renal carcinoma, liver cancer, ovarian cancer, ovary endometriosis, testicular cancer, gastrointestinal cancer, prostate cancer, glioblastoma, skin cancer, melanoma, neuro cancers, spleen cancers, pancreatic cancers, blood proliferative disorders, lymphoma, leukemia, endometrial cancer, cervical cancer, vulva cancer, prostate cancer, penile cancer, bone cancers, muscle cancers, soft tissue cancers, intestinal or rectal cancer, anal cancer, bladder cancer, bile duct cancer, ocular cancer, gastrointestinal stromal tumors, neuro-endocrine tumors, resistance by transplantation of heart, kidney, liver, medulla ossium, skin, cornea, lung, pancreas, intestinum tenue, limb, muscle, nerves, duodenum, small-bowel, or pancreatic-islet-cell; graft-versus-host diseases brought about by medulla ossium transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, and glomerulonephritis.

[4446](#). Use of a compound of any of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, in the manufacture of a medicament for treating cancer.

[4547](#). Use of a compound of any of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, in the manufacture of a medicament for treating an immune-mediated disease selected from resistance by transplantation of heart, kidney, liver, medulla ossium, skin, cornea, lung, pancreas, intestinum tenue, limb, muscle, nerves, duodenum, small-bowel, or pancreatic-islet-cell; graft-versus-host diseases brought about by medulla ossium transplantation; rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes, uveitis, allergic encephalomyelitis, and glomerulonephritis.

[4648](#). Use of a compound of any of claims 1-[3436](#), or a pharmaceutically acceptable salt, [stereoisomer](#), oxepane isomer, or tautomer thereof, in the manufacture of a medicament for treating ~~a an age-related~~ condition selected from sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, pulmonary emphysema, osteoporosis, osteoarthritis, high blood pressure, erectile dysfunction, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, diminished life expectancy, impaired kidney function, and age-related hearing loss, aging-related mobility disability (e.g., frailty), cognitive decline, age-related dementia, memory impairment, tendon stiffness, heart dysfunction such as cardiac hypertrophy and systolic and diastolic dysfunction, immunosenescence, cancer, obesity, and diabetes.